

UNIVERSITI TEKNOLOGI MARA

**TIME AND DOSE DEPENDENT
EFFECTS OF RENIN ANGIOTENSIN
SYSTEM INHIBITORS ON
EXTRACELLULAR MATRIX
DEPOSITION AND MODULATING
ENZYMES IN DEXAMETHASONE
TREATED HUMAN TRABECULAR
MESHWORK CELLS**

NURUL AINSYA BINTI BAKRY

MSc

August 2019

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Nurul Ainsya binti Bakry

Student I.D. No. : 2014923207

Programme : Master of Medical Science (Pharmacology) - MD758

Faculty : Medicine

Thesis Title : Time and Dose Dependent Effects of Renin
Angiotensin System Inhibitors on Extracellular Matrix
Deposition and Modulating Enzymes in
Dexamethasone Treated Human Trabecular
Meshwork Cells

Signature of Student :

Date : August 2019

ABSTRACT

Trabecular meshwork remodeling leads to aqueous humor outflow resistance and increases in intraocular pressure, one of the major risk factors for glaucoma. Trabecular meshwork remodeling is associated with excessive deposition of extracellular matrix components such as collagen, fibronectin, and α -smooth muscle actin, and reduction in the production of matrix metalloproteinases responsible for the extracellular matrix degradation. Inhibitors of the renin angiotensin system were shown to reduce intraocular pressure in animals and clinical studies. They are also well known to attenuate tissue remodelling in the cardiovascular system, however, their effects on human trabecular meshwork have not been investigated yet. The dose and time-dependent effects of RAS inhibitors on extracellular matrix in dexamethasone treated human trabecular meshwork cells, as well as the mechanisms involved in anti remodeling effects of the renin angiotensin system inhibitors were investigated in this study for the first time. The long-time effects of dexamethasone on human trabecular meshwork cells were investigated as well. Human trabecular meshwork cells were cultured in Dulbecco's Modified Eagle's medium, dexamethasone 10^{-7} M, or dexamethasone 10^{-7} M with enalaprilat dihydrate or losartan potassium in concentrations of 10^{-4} , 10^{-5} , 10^{-6} , and 10^{-7} M. All groups were incubated for 7 and 14 days. The same grouping and the time points were used for the study of the effects of the renin angiotensin system inhibitors on human trabecular meshwork cells initially pretreated with dexamethasone for 14 days. MTS assay was done to evaluate cell viability. Immunocytochemistry, western blot, and ELISA were performed to measure extracellular matrix deposition, modulating enzymes, TGF- β 2, uPA, and tPA levels. Dexamethasone significantly increased the production of fibronectin and α -smooth muscle actin compared to that in media only treated cells at both time points. At the same time, dexamethasone decreased the production of both MMP-2 and MMP-9. TIMP-1 and -2 levels were increased at both time points but reached the significantly higher levels only on day 14. The renin angiotensin system inhibitors significantly reduced production of fibronectin and α -smooth muscle actin in both dexamethasone co- and pretreated HTM cells. Both tested renin angiotensin system inhibitors also increased levels of MMPs. Antiremodeling effect of the renin angiotensin system inhibitors was seen in a dose-independent manner, and all tested parameters reached significantly different levels by week 2 of the treatment. The mechanism of attenuation dexamethasone-induced changes in the human trabecular meshwork cells was associated with significantly enhanced secretion of uPA and suppression of TIMPs secretion. The findings suggest that both groups angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are attractive as new options for the treatment and prevention of steroid-induced glaucoma as well as other forms of open angle glaucoma.

ACKNOWLEDGEMENT

Firstly, I wish to thank God for giving me the opportunity to embark on my Master and for completing this long and challenging journey successfully. My gratitude and thanks go to my supervisor Assoc. Prof. Dr. Anna Krasilnikova for her willingness to take me as her student and for all knowledge and guidance she gave me, my co-supervisors; Assoc. Prof. Dr. Igor Iezhitsa, and Prof. Dr Nafeeza Mohd Ismail for all their support and assistance.

My appreciation goes to IMMB as well as Center for Neuroscience Research and their staff who provided the facilities and assistance during my labwork. Special thanks to my colleagues and friends (Adrian, Aizudin, Azliana, Lidawani, Natasha, and Normie) for helping me with this project

Finally, this thesis is dedicated to my family especially my beloved mother; Halimatul Saadiah binti Hussein, my late father; Bakry bin Chik; my lovely siblings; Ainman, Asyikin, Atikah, Syafik, and Aisyah for the vision and determination to educate me and supporting me physically and mentally.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR’S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xix
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the Study	1
1.2 Problem Statement	2
1.3 Hypothesis	2
1.4 Research Questions	2
1.5 Research Objectives	3
1.6 Significance of Study	3
1.7 Scope of Study	4
1.8 Limitation of Study	4
CHAPTER TWO: LITERATURE REVIEW	5
2.1 Glaucoma	5
2.1.1 Definition of Glaucoma	5
2.1.2 Prevalence of Glaucoma	5
2.1.3 Glaucoma Risk Factor and Diagnosis	6
2.1.4 Classification of Glaucoma	7
2.1.4.1 <i>Primary Open Angle Glaucoma (POAG)</i>	7
2.1.4.2 <i>Primary Angle Closure Glaucoma (PACG)</i>	9
2.1.4.3 <i>Developmental Glaucoma</i>	9